PLoS ONE (Jan 2023)

Anti-SARS-CoV-2 antibody kinetics up to 6 months of follow-up: Result from a nation-wide population-based, age stratified sero-epidemiological prospective cohort study in India.

  • Puneet Misra,
  • Arvind Kumar Singh,
  • Baijayantimala Mishra,
  • Bijayini Behera,
  • Binod Kumar Patro,
  • Guruprasad R Medigeshi,
  • Hari Shanker Joshi,
  • Mohammad Ahmad,
  • Pradeep Kumar Chaturvedi,
  • Palanivel Chinnakali,
  • Partha Haldar,
  • Mohan Bairwa,
  • Pradeep Kharya,
  • Rahul Dhodapkar,
  • Ramashankar Rath,
  • Randeep Guleria,
  • Sanjay Kumar Rai,
  • Sitanshu Sekhar Kar,
  • Shashi Kant,
  • Sonali Sarkar,
  • Subrata Baidya,
  • Suneeta Meena,
  • Suprakash Mandal,
  • Surekha Kishore,
  • Tapan Majumder,
  • Vivek Hada

DOI
https://doi.org/10.1371/journal.pone.0287807
Journal volume & issue
Vol. 18, no. 12
p. e0287807

Abstract

Read online

Repeated serological testing tells about the change in the overall infection in a community. This study aimed to evaluate changes in antibody prevalence and kinetics in a closed cohort over six months in different sub-populations in India. The study included 10,000 participants from rural and urban areas in five states and measured SARS-CoV-2 antibodies in serum in three follow-up rounds. The overall seroprevalence increased from 73.9% in round one to 90.7% in round two and 92.9% in round three. Among seropositive rural participants in round one, 98.2% remained positive in round two, and this percentage remained stable in urban and tribal areas in round three. The results showed high antibody prevalence that increased over time and was not different based on area, age group, or sex. Vaccinated individuals had higher antibody prevalence, and nearly all participants had antibody positivity for up to six months.